These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 11433183

  • 1. Studies on the antithrombotic action of AT1 receptor antagonists.
    Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E.
    Med Sci Monit; 2001; 7(4):600-5. PubMed ID: 11433183
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
    Chłopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ.
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):715-22. PubMed ID: 11192944
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.
    Matys T, Kucharewicz I, Pawlak R, Chabielska E, Domaniewski T, Buczko W.
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):710-3. PubMed ID: 14639091
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
    Núñez A, Gómez J, Zalba LR, Montón M, Jiménez A, Velasco S, López-Blaya A, Uriarte AC, Casado S, López-Farré A.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):175-9. PubMed ID: 11967810
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Schwemmer M, Sommer O, Bassenge E.
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
    [Abstract] [Full Text] [Related]

  • 11. Binding of valsartan to mammalian angiotensin AT1 receptors.
    de Gasparo M, Whitebread S.
    Regul Pept; 1995 Nov 10; 59(3):303-11. PubMed ID: 8577935
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
    Li P, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 1997 Jun 10; 281(3):1065-70. PubMed ID: 9190837
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
    Verheijen I, Fierens FL, Debacker JP, Vauquelin G, Vanderheyden PM.
    Fundam Clin Pharmacol; 2000 Jun 10; 14(6):577-85. PubMed ID: 11206708
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The involvement of AT(2)-receptor in the antithrombotic effect of losartan in renal hypertensive rats.
    Chabielska E, Matys T, Kucharewicz I, Pawlak D, Rólkowski R, Buczko W.
    J Renin Angiotensin Aldosterone Syst; 2000 Sep 10; 1(3):263-7. PubMed ID: 11881035
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.